Clinical trials: Prurigo Nodularis
Prurigo Nodularis
Safety and Efficacy of Nemolizumab in PN
The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.
- Trial name
- NCT03181503
- Testing
- CD14152 Dose A
- Where
- 16 sites in Austria, France and 2 more
- Volunteers
- 70 people
- Sponsor
- Galderma R&D
Prurigo Nodularis
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
- Trial name
- NCT06213831
- Testing
- Ruxolitinib Cream 1.5%
- Where
- 20 sites in United States
- Volunteers
- 23 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis Eczema, Prurigo Nodularis
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2…
- Trial name
- CORNERSTONE (NCT05316805)
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Peking University First Hospital
Atopic Dermatitis, Prurigo Nodularis
Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life
The primary objective of this open randomised controlled trial is to assess the add-on effect of EMD-U compared to CAU alone, in improving dermatology-specific quality of life in patients with atopic dermatitis or prurigo…
- Trial name
- EMD-U vs CAU (NCT06427122)
- Testing
- EMD Protocol for Urge, Care as Usual
- Where
- Netherlands
- Volunteers
- 96 people
- Sponsor
- Tamar Nijsten
Pruritus, Prurigo Nodularis
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
- Trial name
- NCT03546816
- Testing
- 5mg Serlopitant Tablets
- Where
- 49 sites in United States
- Volunteers
- 285 people
- Sponsor
- Vyne Therapeutics Inc.
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
- Trial name
- NCT06516965
- Testing
- Povorcitinib
- Where
- 119 sites in United States, Australia and 9 more
- Volunteers
- 346 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease
The development of the topical calcineurin inhibitor pimecrolimus resulted in a significant improvement in the treatment of atopic dermatitis. In addition, an excellent amelioration of pruritus could be regularly observed.
- Trial name
- CASM981CDE21 (NCT00507832)
- Testing
- Pimecrolimus, Hydrocortisone
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Muenster
Prurigo Nodularis
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: Screening period: 2 to 4 weeks. Treatment period: 24 weeks. Post-intervention follow-up period: 16 weeks.
- Trial name
- NCT06293053
- Testing
- Dupilumab
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sanofi
Prurigo Nodularis
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules.
- Trial name
- CLEAR PN (NCT06087627)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 11 sites in Germany
- Volunteers
- 110 people
- Sponsor
- Sanofi
Prurigo Nodularis
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.
- Trial name
- NCT06554509
- Testing
- SHR-1819 Injection
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Prurigo Nodularis
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
The main objective of this study is to assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab in participants with prurigo nodularis (PN) who previously responded to treatment in the…
- Trial name
- NCT05052983
- Testing
- Nemolizumab
- Where
- 14 sites in United States, Austria and 5 more
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Prurigo Nodularis (PN)
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
- Trial name
- NCT07236099
- Testing
- ICP-322
- Where
- 43 sites in United States, China and 3 more
- Volunteers
- 135 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Prurigo Nodularis
Upadacitinib for Prurigo Nodularis
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
- Trial name
- NCT06773403
- Testing
- Upadacitinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Prurigo Nodularis, Pruritus
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe…
- Conditions
- Prurigo Nodularis, Pruritus, Chronic Pruritus, Chronic Prurigo
- Trial name
- NCT05038982
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Prurigo Nodularis
Safety and Efficacy of CC-10004 for Prurigo Nodularis
This trial will include: Study period up to 7 months. Office visits monthly lasting approximately 1 hour. Blood Draws. Oral medication that is taken 2 times daily. Photographs and biopsies if agreed.
- Trial name
- NCT00869089
- Testing
- CC-10004
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University Hospitals Cleveland Medical Center
Prurigo Nodularis
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.
- Trial name
- NCT06779136
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension…
- Trial name
- NCT05061693
- Testing
- INCB054707
- Where
- 49 sites in United States, Canada and 4 more
- Volunteers
- 146 people
- Sponsor
- Incyte Corporation
Chronic Pruritus, Eczema
Efficacy of Topical Cannabidiol for Eczema
Itching is a common symptom encountered in general medical practice. It can cause significant discomfort, disrupt sleep, and impair patients' quality of life.
- Conditions
- Chronic Pruritus, Eczema, Nummular Eczema, Atopic Dermatitis
- Trial name
- NCT06994520
- Testing
- Cannabidiol (CBD), Triamcinolone (TAC) 0.1% cream
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Khon Kaen University
Prurigo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN1 (NCT05755438)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 71 sites in United States, Argentina and 9 more
- Volunteers
- 204 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
- Trial name
- NCT04204616
- Testing
- Nemolizumab
- Where
- 164 sites in United States, Austria and 14 more
- Volunteers
- 500 people
- Sponsor
- Galderma R&D